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A B S T R A C T
Currently drug eluting stents (DES) have reached a high degree of sophistication where there seems very
little scope of improvement. Even so every year or so there is some advancement in technology and a new
version is released, which is claimed to be a new generation (rather than pipeline innovation). It is really
important to deﬁne what pipeline extension is and what is new innovation (generation)? This
classiﬁcation would not only be useful from regulatory perspective but also determining the true value of
a product allowing for a correct pricing, which should ideally be able to mark-up for a real innovation.
 2016 Cardiological Society of India. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Stents (as they are available in cath lab) are essentially
composed of 4 components: Bare stent, anti-restenotic drug,
polymer, and delivery system. The stent itself has several
components relevant to clinical outcome; stent material, strut
thickness, and stent design. Evolution occurs in all these
components so much so that latest generation stents are quite
different from the so called ‘‘ﬁrst generation’’ stents in technical
speciﬁcations. But leave aside technicalities, even outcomes of
current generation DES are much superior to ﬁrst generation DES
and this has led to extinction of some earlier stent.1,2 SPIRIT-II trial
(300 patients) revealed that Xience V stent (3rd generation) was
superior to Taxus stent (1st generation) effecting signiﬁcant
reduction in late loss (0.12 vs. 0.37 for Taxus, p < 0.001) and a
numerical reduction in binary restenosis. (1.3% vs. 3.5%; p = 0.194),
and target lesion revascularization [TLR] (2.7% vs. 6.5%; p = 0.157).
In addition, cardiac death, myocardial infarction [MI] and stent
thrombosis was also numerically less (although did not reach
statistical signiﬁcance).3 Subsequently, the SPIRIT-III, a random-
ized controlled, multi-centric study, comparing Xience V with
Taxus stent also revealed that at the end of 2 years, Xience V
showed superior results; target vessel failure [TVF] showed a 32%
reduction (10.7 vs. 15.4%, hazard ratio [HR] 0.68, 95% conﬁdence
interval [CI] 0.48–0.98; p = 0.04) and a 45% reduction in major
adverse cardiac events [MACE] (7.3 vs. 12.8%, HR 0.55, 95% CI 0.36–
0.83; p = 0.004).4 SPIRIT IV randomized 3690 patients to receive
the Xience V or Taxus stent. At 1 year follow-up the stent
thrombosis was lower with Xience V (0.29% vs. 1.06%, p = 0.003). At
3 years there was a 43% and 39% reduction in MACE and TLR.5
Another real-world trial compared Xience V with Taxus, random-
izing 1800 patients (pts.). The primary end-point was a composite
of all-cause mortality, non-fatal MI and target vessel revasculari-
zation [TVR] within 12 months and was signiﬁcantly less in thehttp://dx.doi.org/10.1016/j.ihj.2016.08.012
0019-4832/ 2016 Cardiological Society of India. Published by Elsevier B.V. This is an
licenses/by-nc-nd/4.0/).Xience group (6% vs. 9%, relative risk 0.69, 95% CI 0.50–0.95;
p = 0.02 for superiority). Further, Xience V stent was also
associated with signiﬁcantly less stent thrombosis (p = 0.002).6
Thus evolution of stents represents not only marked improvement
in efﬁcacy but also in safety (stent thrombosis, MI at one year).
These differences in outcomes could be explained by differences in
the underlying stent platforms, the anti-restenotic drug or the
polymer eluting the drug.7
1.1. Deﬁnitions
Pipeline products: pipeline products are those medical device
technologies currently in the pipeline for commercialization.
Regulation wise, pipeline products work on the concept of
‘‘substantial equivalency’’ i.e. if a product is similar enough to
one already on the market and proven to be safe, it can gain
approval without clinical trials. But pipeline products do represent
an advance in the ﬁeld whether it is improved efﬁcacy or safety but
mostly ease of use. Improvement in device delivery technology
represents a good example of pipeline extension.
Next-generation products (aka platform products) are innova-
tions which should satisfy 4 criteria8:
1. Address the felt-needs in a particular ﬁeld.
2. Lead to substantial improvement in the range and efﬁciency of a
product.
3. Incorporate signiﬁcant improvements in performance and cost
over the preceding generation.
4. Provide a path for current users to migrate from the older
product.
Thus next-generation products require a major commitment of
resources by the innovators but they are expected to inspire and
support a whole new line of derivative products by the competitors. open access article under the CC BY-NC-ND license (http://creativecommons.org/
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The proof of the pudding is in eating and the bottom-line for any
medical technology is if it can be proven to beneﬁt the recipient or
end-user. In other words outcome data is the most valuable proof
of usefulness of any stent. However, in clinical situations
particularly in context of medical devices there are several
limitations to an approach purely based on data acquisition.
1. The most important limitation is that it takes a huge amount of
time for data to accrue; typically hard data is obtained only after
minimum of three-ﬁve years follow-up, but by this time several
innovations have already happened and the older device that
has accumulated this kind of data may already be antiquated. A
case in point is Cypher/Taxus stent, which probably have the
maximum amount of data but are no longer in use.
2. The second limitation is number of pts. required for a
meaningful outcome may be huge especially if hard end-points
are considered, making the study not only very expensive but a
logistics nightmare as well.
3. Variability of end-points chosen; late loss, event rate, TLR, TVR,
re-stensosis, TVF, mortality, etc. Some of these end-points, e.g.
late loss are soft but some others like stent thrombosis or
mortality are hard. The value of each study whether observa-
tional or randomized control trial will also be different
depending on these variables.
4. The quality of study may also be different, randomized
controlled trial, observational study, case report have different
connotations.
5. The quality of data can also be widely variable, unpublished data
is inferior to published data but in a non indexed journal, which
is inferior to that published in peer-reviewed indexed journal.
Clearly one cannot totally rely on data alone or technical
features alone. There is a need to integrate both technical
features and data to come out with a score determining the real
value of a stent (innovation). In choosing data the quality of data
is very important; at the minimum it should be obtained from
peer-reviewed, indexed journals. In choosing the technical
speciﬁcations, those features should be chosen which have a
proven impact on clinical outcome or interventionist’s ease
of use.Table 1
Score for stent classiﬁcation.
Stent Polymer 
Material 
Stainless steel 0 Biocompatible  10 m
Cobalt chromium 1 Biocompatible < 10 m
Platinum chromium 2 Bio-resorbable  10 
Bio-absorbable 3 Bio-resorbable < 10 
Stent strut thickness
150 m 0 
100 m 1 
80 m 2 
<80 m 3 
Design
Spiral 0 
Slotted tube 1 
Hybrid 2 
Advanced special design features 3 3. Clinical outcomes vs. ease of use
Clinical outcomes can be efﬁcacy or safety. They vary from late
loss, event rate, TLR, TVR, re-stensosis, rate of coronary artery
bypass grafting to stent fracture, stent thrombosis, stroke rate,
bleeding risks to mortality. End-user usability characteristics can
vary from visibility of stent while implantation (radio-opacity),
deliverability, ability to implant without vessel preparation, need
for imaging modalities. There could be some cost outcomes as well,
for example ability to deploy one long stent instead of two short
ones can save on cost.
4. What about US FDA and European CE?
US FDA and European CE Mark also look at the efﬁcacy and
safety data before certifying a stent for clinical use in their
respective countries, so is there a need to re-invent the wheel? The
reality is that FDA and European CE are approvals for marketing,
are focused on safety and but no indicators of relative clinical value
of different stents. Further, FDA is constrained by several
limitations. Foremost is a long time in the approval process, it
even requires repetition of study in US sites, even if similar data is
already available from other countries. However, a major
limitation is that there is no mechanism of recall, so much so
that the stents remain approved even if they have long over-lived
their usefulness and even become obsolete. On the other hand, the
major limitation of CE mark is the wide variability in the quality,
depending on the country of marking.
5. How to classify/score a stent
To understand the value of a given stent and for the purpose of
comparison between various available stents it is imperative to
develop an objective scoring system. For classiﬁcation of stents
considerations of both technical aspects and outcome data should
be made. Among technical features those that have a bearing on
outcome should be considered. Each point can be scored according
to degree of advancement and potential clinical/user beneﬁt.
Table 1 proposes a simple objective scoring system to achieve such
an outcome. The maximum score possible is 20. Stent can be
classiﬁed according to scores achieved, Table 2. For ﬁrst generation
score is <6, second generation a score between 6–11, thirdData (meta-analysis of all studies available), %
No data 0
 0 MACE – 1 year
 1 >9 0
m 2 6–9 1
m 3 <6 2
Target vessel failure – 1 year
5 0
3–5 1
<3 2
Stent thrombosis – 1 year
>1 0
0.5–1 1
<0.5 2
Mortality – 1 year
>2 0
1–2 1
<1 2
Table 2
Stent classiﬁcation based on score.
Score
1st generation <6
2nd generation 6–11
3rd generation 12–16
4th generation >16
Editorial / Indian Heart Journal 68 (2016) 589–591 591generation 12–16 and fourth generation 17 and above. This
classiﬁcation categorizes stents according to contemporary useful-
ness and can serve as a mechanism for ﬁxing their appropriate
prices.
6. Future validation
This score will require validation in future studies but this will
take a long time and it is important to have something in place to
solve immediate needs.
7. Conclusions
As stent technology evolves there is improvement in efﬁcacy
and safety. However, there is a need to objectively establish
usefulness of stents. This may have impact on rational pricing of
these devices.References
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